USA: +1 617 939 9497 | UK: +44 2039 962936 | EU: +34 607 939 266 info@sofpromed.com
Select Page

Klindat: Affordable EDC Solution for Real-World Evidence Studies

Patricio Ledesma

Head Of Clinical Operations at Sofpromed

20 June, 2024

Klindat Affordable EDC Solution for Real-World Evidence Studies

Please contact us at info@sofpromed.com if you wish to learn more about Klindat EDC

In the ever-evolving landscape of healthcare research, the emergence of Real-World Evidence (RWE) studies has transformed the way we generate and utilize clinical insights.

In this article you will learn about:

These studies, which leverage real-world data (RWD) from diverse sources, offer a more comprehensive understanding of treatment outcomes, safety, and effectiveness in actual clinical practice.

However, the cost of traditional Electronic Data Capture (EDC) systems has often been a significant barrier for many clinical trial sponsors, particularly those with limited budgets.

Klindat is a game-changing EDC platform that is revolutionizing the way researchers and healthcare professionals approach RWE studies.

Developed by the pioneering company Zlynger, Klindat is a low-cost, yet highly capable EDC system designed to cater to the needs of academic, non-profit, and publicly funded research initiatives.

In this comprehensive article, we’ll explore the significance of RWE studies, the key features and benefits of the Klindat EDC system, and how this affordable solution is transforming the landscape of clinical data management.

Understanding the Importance of Real-World Evidence (RWE) Studies

Real-World Evidence (RWE) studies have become increasingly crucial in the healthcare industry, as they provide a deeper understanding of how treatments and interventions perform in real-world settings.

Unlike traditional clinical trials, which are conducted in controlled environments, RWE studies analyze data from diverse patient populations, capturing the nuances and complexities of everyday clinical practice.

The primary advantages of RWE studies include:

Broader Patient Representativeness

RWE studies often include a wider range of patients, including those with comorbidities and diverse demographic characteristics, providing a more accurate assessment of treatment outcomes across different subgroups.

Long-Term Safety Monitoring

RWE studies enable the long-term monitoring of drug safety, allowing for the identification of potential adverse effects that may only become apparent after prolonged use.

Comparative Effectiveness Research

RWE studies facilitate the comparison of different treatment options, helping healthcare professionals make informed decisions based on real-world evidence.

Healthcare Cost Analysis

RWE studies can provide valuable insights into the economic impact of treatments, including healthcare resource utilization and costs, which is crucial for policymakers and payers.

By leveraging RWE, researchers, healthcare providers, and policymakers can make more informed decisions, improve patient care, and advance medical knowledge in a way that traditional clinical trials alone cannot.

The Limitations of Traditional EDC Systems

While the benefits of RWE studies are well-recognized, the cost of traditional EDC systems has often been a significant barrier for many clinical trial sponsors, especially those with limited budgets.

These conventional EDC platforms typically involve substantial initial start-up costs and monthly subscription fees, making them inaccessible for many academic, non-profit, and publicly funded research initiatives.

The high price tag of traditional EDC systems can be a significant challenge for researchers and study sponsors who are already operating with constrained resources.

This financial burden can limit their ability to invest in robust data management solutions, potentially compromising the quality and reliability of the collected data.

To address this issue, there is a pressing need for affordable EDC tools that can cater to the budgetary constraints of these clinical research organizations, while still providing the necessary functionality and compliance required by the industry.

Introducing Klindat: The Low-Cost EDC Solution for RWE Studies

Recognizing the need for a more affordable EDC platform, the team at Zlynger has developed Klindat – a cost-effective, yet highly capable EDC system specifically designed for RWE studies.

Klindat stands out as a game-changer in the world of clinical data management, offering a compelling quality-price ratio that enables academic, non-profit, and publicly funded research initiatives to conduct their studies with confidence and efficiency.

Simplicity and User-Friendliness

One of the key strengths of Klindat is its intuitive interface and user-friendly design.

Accessible via the internet with no installations required, the platform is compatible with multiple devices and browsers, ensuring a seamless experience for researchers, healthcare providers, and study participants alike.

This simplicity and ease of use make Klindat an excellent choice for researchers and clinicians who may have limited technical expertise, allowing them to navigate the system effortlessly.

Robust Security and Reliability

Data security is of paramount importance in clinical research, and Klindat addresses this concern with a comprehensive set of measures.

The platform employs robust access control mechanisms, SSL encryption, and daily backups to ensure the confidentiality and integrity of the collected data.

Klindat also complies with industry standards, such as the Health Insurance Portability and Accountability Act (HIPAA), Good Clinical Practice (GCP), and 21 CFR Part 11, ensuring the highest level of security and reliability.

Powerful Data Management and Customizable Reporting

Klindat offers a wide range of features that streamline data management tasks and empower researchers and study sponsors to generate comprehensive reports.

The platform is adaptable to studies of any size and provides extensive customization options, allowing users to tailor the system to their specific needs.

From data entry and validation to real-time monitoring and reporting, Klindat simplifies the data management process, enabling researchers to optimize workflows and generate insightful reports with ease.

Cloud Storage and Document Uploads

In addition to its core data management capabilities, Klindat offers cloud storage options for uploading various documents, including Word files, PDFs, and even medical images in DICOM format.

Researchers and study sponsors can easily organize and access these documents within the platform, enhancing collaboration and facilitating comprehensive data analysis.

Transparent Pricing Model

One of the most compelling aspects of Klindat is its transparent and straightforward pricing model, which is designed to cater to the budgetary constraints of academic sponsors.

The initial build cost, which involves defining specifications and building the necessary forms, typically ranges between $3,000 and $8,000, depending on the complexity of the study.

Furthermore, the monthly usage and hosting subscription fee is highly competitive, ranging between $300 and $800 per month, based on the number of patients included in the study.

This flexible pricing model ensures that sponsors only pay for the services they need, making Klindat an attractive option for studies with limited budgets.

Klindat’s Impact on Real-World Evidence Studies

The introduction of Klindat has had a significant impact on the landscape of RWE studies, empowering researchers and healthcare professionals to conduct their studies with confidence and efficiency, even with limited financial resources.

Enabling Affordable Data Collection and Management

By offering a low-cost EDC solution, Klindat has removed a significant barrier that had previously hindered many academic, non-profit, and publicly funded research initiatives from leveraging the power of RWE.

With its transparent pricing and customizable features, Klindat enables these organizations to invest in robust data management solutions without breaking the bank, ensuring the quality and reliability of their research findings.

Enhancing Data Quality and Compliance

Klindat’s focus on security, reliability, and compliance with industry standards, such as HIPAA and GCP, ensures that the data collected in RWE studies meets the highest quality and regulatory requirements.

This, in turn, enhances the credibility and acceptance of the research findings, making them more valuable for healthcare decision-making and policy development.

Empowering Researchers and Clinicians

By providing an intuitive and user-friendly platform, Klindat empowers researchers and clinicians, even those with limited technical expertise, to actively participate in RWE studies.

This democratization of data management tools fosters greater collaboration and engagement, ultimately leading to more robust and impactful research outcomes.

Klindat’s Versatility in Real-World Evidence Studies

Klindat’s capabilities extend beyond just being an affordable EDC solution; the platform has proven to be a versatile tool in a wide range of RWE study applications.

Clinical Trials and Drug Development

Klindat plays a crucial role in clinical trials and drug development by enabling researchers to capture real-world data from diverse patient populations.

This data, collected from sources such as electronic health records, patient-reported outcomes, and wearable devices, provides invaluable insights into the safety and effectiveness of new treatments, informing decision-making throughout the drug development process.

Post-Market Surveillance Studies

In the realm of post-market surveillance studies, also known as Phase IV studies, Klindat shines as a streamlined data collection and management platform.

By facilitating the timely and efficient capture of real-world data from large patient populations, Klindat enables researchers to monitor the long-term safety and effectiveness of approved medical products, supporting regulatory decision-making and patient safety.

Patient Registries and Disease Surveillance

Klindat’s versatility extends to patient registries and disease surveillance programs, where the platform’s customizable forms, centralized data management, and real-time reporting capabilities simplify the collection, analysis, and monitoring of disease patterns, treatment outcomes, and patient experiences.

This empowers researchers and healthcare providers to gain valuable insights into disease prevalence, treatment effectiveness, and long-term patient outcomes.

Comparative Effectiveness Research

Klindat’s ability to integrate data from multiple sources, such as electronic health records and patient-reported outcomes, makes it an invaluable tool for comparative effectiveness research.

By enabling the analysis of real-world data from diverse patient populations, Klindat supports researchers in comparing the benefits and harms of different treatment options, ultimately informing evidence-based decision-making and improving patient care.

Considerations in Selecting an RWE EDC Solution

When choosing an EDC software for real-world evidence studies, it is essential to consider several key factors to ensure the solution aligns with your research objectives and budget.

Ease of Use and Flexibility

Look for an EDC platform that offers an intuitive and user-friendly interface, allowing researchers, healthcare providers, and study participants to navigate the system effortlessly.

Additionally, the software should provide flexibility in study design, enabling researchers to tailor the system to their specific needs and research questions.

Data Integration and Standardization

Prioritize EDC software that can seamlessly integrate data from various sources, such as electronic health records, wearable devices, and patient-reported outcomes.

This integration enhances the richness and comprehensiveness of real-world data analysis.

Furthermore, the software should ensure data standardization, minimizing the need for manual data transcription and improving overall data quality.

Data Security and Regulatory Compliance

Ensure that the EDC software adheres to relevant regulatory standards, such as 21 CFR Part 11, GDPR, GCP, and HIPAA.

Robust data security measures, including encryption, access controls, and audit trails, should be in place to protect patient privacy and maintain data integrity.

Real-Time Monitoring and Reporting

Select an EDC software that provides real-time monitoring and reporting capabilities, enabling researchers to track study progress, identify data quality issues, and generate reports on-demand.

This feature facilitates prompt intervention and ensures the accuracy and completeness of the collected data.

Customization and Support

Consider an EDC software that allows for the customization of study forms, workflows, and reporting options.

This customization ensures that the platform aligns with your specific research objectives and enhances the overall data collection and management processes.

Additionally, look for a provider that offers comprehensive support and training to researchers, healthcare providers, and study participants, ensuring the effective utilization of the software.

By carefully evaluating these factors, you can identify an EDC solution that not only meets your budgetary constraints but also empowers you to conduct high-quality real-world evidence studies that drive meaningful advancements in healthcare.

Conclusion: Embracing Klindat for Affordable and Reliable RWE Studies

In the dynamic landscape of healthcare research, the advent of Klindat has ushered in a new era of affordable and reliable real-world evidence studies.

By offering a cost-effective EDC solution that prioritizes simplicity, security, and compliance, Klindat has removed a significant barrier that had previously hindered many academic, non-profit, and publicly funded research initiatives from leveraging the power of RWE.

Klindat’s versatility and customization capabilities make it an ideal choice for a wide range of RWE study applications, from clinical trials and post-market surveillance to patient registries and comparative effectiveness research.

As the demand for real-world insights continues to grow, the Klindat EDC system stands as a game-changer, democratizing access to robust data management solutions and paving the way for more affordable, efficient, and impactful real-world evidence studies.

By embracing Klindat, researchers, healthcare providers, and policymakers can unlock new possibilities in healthcare and contribute to a future where evidence-based decision-making is the norm, not the exception.

Please contact us at info@sofpromed.com if you wish to learn more about Klindat EDC

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266  pledesma@sofpromed.com 

You may also be interested…

Klindat: The Low-Cost Patient Registry Software

Klindat: The Low-Cost Patient Registry Software

Please contact us at info@sofpromed.com if you need more information about Klindat EDC software for patient registries In the dynamic landscape of healthcare, patient registries have emerged as powerful tools, revolutionizing the way we understand diseases, develop...

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266 pledesma@sofpromed.com